Cytotoxic effects of sodium phenylbutyrate on human neuroblastoma cell lines

International Journal of Oncology

Volumn 12, Issue 4, 1998, Pages 889-893

  Pelidis, Maria A ^a   Carducci, Michael A ^b   Simons, Jonathan W ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Differentiation; Growth inhibition; Neuroblastoma; Sodium phenylbutyrate; Vincristine

Indexed keywords

2 PHENYLBUTYRATE SODIUM; 4 HYDROXYCYCLOPHOSPHAMIDE; ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; CISPLATIN; DOXORUBICIN; ETOPOSIDE; UNCLASSIFIED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CHILDHOOD CANCER; CONCENTRATION RESPONSE; DRUG CYTOTOXICITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; NERVE CELL DIFFERENTIATION; NEUROBLASTOMA CELL; PRIORITY JOURNAL;

EID: 0031939919     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.4.889     Document Type: Article

References (16)

1. Brodeur GM and Castleberry RP: Neuroblastoma. In: Principles and Practice of Pediatric Oncology. 2nd edition. Pizzo PA and Poplack DG (eds). J.B. Lippincott, Philadelphia, pp739-767, 1992.
2. Sidell N, Wada R, Han G, Chang B, Shack S, Moore T and Samid D: Phenylacetate synergizes with retinoic acid in inducing the differentiation of human neuroblastoma cells. Int J Cancer 60: 507-514, 1995.
3. Abemayor E, Chang B and Sidell N: Effects of retinoic acid on the in vivo growth of human neuroblastoma cells. Cancer Lett 55: 1-5, 1990.
4. Sidell N, Altman A, Haussler MR and Seeger RC: Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines. Exp Cell Res 148: 21-30, 1983.
5. Villablanca JG, Khan AA, Avramis VI, et al: Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol 13: 894-901, 1995.
6. Brusilow SW, Danney M, Waber LJ, et al: Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis. N Engl J Med 310: 1630-1634, 1984.
7. Collins AF, Pearson HA, Giardina P, McDonagh KT, Brusilow SW and Dover GJ: Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood 85: 43-49, 1995.
8. Fibach E, Prasanna P, Rodgers GP and Samid D: Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and beta-thalassemia. Blood 82: 2203-2209, 1993.
9. Carducci MA, Nelson JB, Chan-Tack K, et al: Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Cancer Res 2: 379-387, 1996.
10. Piscitelli SC, Thibault A, Figg WD, et al: Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine. J Clin Pharmacol 35: 368-373, 1995.
11. Prasanna P, Shack S, Wilson VL and Samid D: Phenylacetate in chemoprevention: in vitro and in vivo suppression of 5-aza-2-deoxycytidine-induced carcinogenesis. Clin Cancer Res 1: 865-867, 1995.
12. Samid D, Shack S and Sherman LT: Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res 52: 1988-1992, 1992.
13. Samid D, Shack S and Myers CE: Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Invest 91: 2288-2295, 1993.
14. Seeger RC, Brodeur GM and Sather H: Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastoma. N Engl J Med 313: 1111-1116, 1985.
15. Danesi R, Nardini D, Basolo F, Del Tacca M, Samid D and Myers CE: Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene. Mol Pharmacol 49: 972-979, 1996.
16. Rocchi P, Ferreri AM, Simone G, Granchi D, Paolucci P and Paolucci G: Growth inhibitory and differentiating effects of sodium butyrate on human neuroblastoma cells in culture. Anticancer Res 12: 917-920, 1992.